Get Your Free Guide to Medicare Drug Negotiation

Understanding Medicare Drug Price Negotiation

Medicare drug price negotiation is a process that allows the federal government to talk directly with pharmaceutical companies about the prices of certain medications. For decades, Medicare was not allowed to negotiate drug prices—this was a rule set by Congress. In 2023, this changed with new legislation that gave Medicare the power to negotiate prices for some of the most expensive drugs used by Medicare beneficiaries.

The negotiation process works like this: Medicare identifies drugs that are used by a large number of people on Medicare and that cost a significant amount of money. The government then sits down with the companies that make these drugs and discusses what price Medicare will pay for them. If the company and Medicare agree on a price, that becomes the new price for people on Medicare prescription drug plans.

This is different from other countries, where governments have negotiated drug prices for many years. In the United States, drug companies have traditionally set their own prices, and Medicare had to pay what they asked. The new rules represent a major shift in how medications are purchased for millions of Americans.

The first round of negotiations resulted in price reductions for ten drugs. These included medications for conditions like diabetes, heart disease, and arthritis. For example, some drugs saw price reductions ranging from 38% to 94% compared to what Medicare was paying before. These negotiations only apply to people on Medicare—they do not affect prices for people with private insurance or those without insurance.

Practical takeaway: Drug price negotiation means that some people on Medicare may pay less for certain medications starting in 2025. The list of drugs that Medicare can negotiate changes over time, and new drugs are added to the list each year.

Which Drugs Are Covered Under Negotiation

Not all medications are included in the drug price negotiation process. Medicare can only negotiate prices for drugs that meet specific requirements. First, the drug must be covered under Part D, which is the prescription drug insurance part of Medicare. Second, the drug must have been on the market for a certain amount of time—at least nine years for most drugs, or thirteen years for drugs called biologics, which are made from living cells.

Third, and most importantly, the drug must be used by a large number of Medicare beneficiaries and must represent a significant cost to the Medicare program. The government looks at which drugs are prescribed most often and which ones cost the most money overall. These are the drugs most likely to be selected for negotiation.

In the first year of negotiations, Medicare negotiated for these ten drugs: Zetia (for cholesterol), Januvia (for diabetes), Farxiga (for heart failure and diabetes), Imbruvica (for blood cancers), Fiasp and Humalog (both insulin), NovoLog (insulin), Xeljanz (for rheumatoid arthritis), Eliquis (for blood clots), and Jardiance (for diabetes). These drugs represent some of the most expensive medications that Medicare pays for each year.

Each year, the list of drugs available for negotiation grows. In 2026, Medicare was able to negotiate for more drugs. The process continues to expand, meaning more and more medications may see price reductions over time. However, newly released drugs cannot be negotiated immediately—they must be on the market for several years first.

It is important to note that even if a drug is being negotiated, people on Medicare may not immediately see a price change. The negotiated price takes effect on January 1 of the following year. This means negotiations that happen in 2024 result in price changes that people see in 2025.

Practical takeaway: Check whether your current medications are on the list of drugs being negotiated. You can find this information on official Medicare websites or by asking your pharmacist. If your drug is not on the list yet, it may be added in future years.

How Price Reductions Affect Your Out-of-Pocket Costs

When Medicare negotiates a lower price for a drug, the reduction can affect what you pay out of your own pocket. However, the exact amount you save depends on your specific situation and your prescription drug plan. Not everyone on Medicare saves the same amount of money, even when the same drug is negotiated.

If you are in the coverage gap—sometimes called the "donut hole"—you may see a more significant savings. The coverage gap is a stage in Medicare Part D where you pay a larger share of your drug costs. When a drug price is negotiated lower, the amount you have to pay during the coverage gap decreases. For some people, a negotiated drug price could mean the difference between affording their medication and skipping doses to save money.

Your actual savings also depend on your insurance plan's formulary, which is a list of drugs that your plan covers. Some plans may pass the full negotiated price reduction to you, while others may keep part of the savings. It is a good idea to contact your insurance company directly to understand how a negotiated price will affect your specific plan.

People who qualify for programs like Medicaid or the Low-Income Subsidy program may also benefit from negotiated prices. These programs help pay for prescription drugs for people with limited incomes. When drug prices go down, the total amount these programs need to pay also goes down.

The Medicare program as a whole saves money when drug prices are lower. This savings can help Medicare stay financially stable over time. Some of these savings are returned to beneficiaries through lower premiums or improved coverage, though the exact impact varies from year to year.

Practical takeaway: Review your Medicare Part D plan documents or call your insurance company to see how negotiated prices affect your costs for drugs you currently take. Your out-of-pocket savings depend on your specific plan, your income level, and what stage of coverage you are in.

How Pharmaceutical Companies Respond to Negotiation

Drug companies have responded to Medicare price negotiations in several ways. Some companies have accepted the negotiated prices and moved forward without major changes. Others have expressed concerns about how lower prices might affect their ability to develop new medications in the future. This is an ongoing debate in healthcare policy.

Some pharmaceutical companies have adjusted their pricing strategies as a result of negotiations. For instance, companies may raise prices for drugs that cannot yet be negotiated, knowing that older drugs will eventually face price negotiations. This is one unintended consequence that some observers have noted.

Several drug manufacturers have filed lawsuits against the government, arguing that the negotiation process violates their rights. These legal challenges are still working their way through the courts. The outcomes of these lawsuits could affect how negotiations proceed in the future and which drugs are included in the program.

Companies have also increased their investment in new drug development and in medications that are not yet on the market. Some argue that this is a positive result, as it encourages innovation. Others worry that negotiated prices may discourage research into treatments for rare diseases that affect fewer people and therefore generate less profit.

Despite these challenges, most major pharmaceutical companies continue to develop new drugs and bring them to market. Drug companies still invest billions of dollars in research and development each year. The negotiation process has not stopped innovation entirely, though some debate continues about what the long-term effects might be.

Practical takeaway: Understand that pharmaceutical companies may respond to price negotiation in various ways, and this could affect drug availability and pricing in the future. Stay informed about changes to your medications or their availability through your doctor, pharmacist, or Medicare.

Steps to Stay Informed About Drug Negotiation Updates

Staying informed about which drugs are being negotiated and what price changes are coming helps you plan for your healthcare costs. The first place to check is the official Medicare website, Medicare.gov. This website publishes annual lists of drugs selected for negotiation and the negotiated prices once they are finalized. The information is updated each year, usually in the fall, for prices that take effect on January 1.

You can also sign up for email updates from Medicare or from your insurance company. Many insurance companies send notices about changes to your prescription drug coverage. These notices typically arrive in the fall and explain what will change in the coming year. Reading these notices carefully helps you understand how your costs might change.

Talking with your pharmacist is another way to stay informed. Pharmacists have detailed knowledge about drug prices and can tell you whether a medication you take is being negotiated. They can also explain how a price change might affect what you pay. Many pharmacists are willing to discuss your medication costs